Distribution and survival of primary sarcoma in Korea: A single center analysis of 2017 cases

Jo, Sung Jun; Kim, Kyeong Sik; Lee, Kyo Won; Park, Jae Berm; Choi, Yoon–La; Yu, Jeong Il; Lee, Su Jin; Choi, Dong Il; Kim, Sung Joo

doi:10.14216/kjco.18005

Korean J Clin Oncol

2018

DOI: 10.14216/kjco.18005

|View full text |Cite

Distribution and survival of primary sarcoma in Korea: A single center analysis of 2017 cases

Sung Jun Jo

Kyeong Sik Kim

Kyo Won Lee

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Secondary hematological malignancies in patients with sarcoma: A single‑center retrospective study

Jang,

Jeong,

Kong

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

The present retrospective study investigated the clinical features and prognosis of secondary hematological malignancies (SHMs) in patients with sarcoma at Korea Cancer Center Hospital (Seoul, South Korea). Patients who had been diagnosed with SHMs after having received treatment for sarcoma between January 2000 and May 2023 were enrolled. Clinical data were collected from the patients' medical records. Clinical characteristics were analyzed, including SHM incidence, type and prognosis. Of 2,953 patients with sarcoma, 18 (0.6%) were diagnosed with SHMs. Their median age at the time of sarcoma diagnosis was 39.5 (range, 9–72) years, and 74% (n=14) of these patients were male. The histological features of sarcoma varied, with osteosarcoma diagnosed in nine patients (50%). All patients with sarcoma underwent surgical treatment, and 16 (88.8%) received chemotherapy. The most common type of SHMs was acute myeloid leukemia (n=6; 33.3%), followed by myelodysplastic syndrome (n=5; 27.7%). The median latency period between the sarcoma diagnosis and SHM identification was 30 (range, 11–121) months. A total of 13 (72.2%) patients received treatment for the SHM. The median overall survival after SHM diagnosis was 15.7 (range, 0.4–154.9) months. The incidence of SHMs in sarcoma in the present study was consistent with that reported previously. The presence of SHMs was associated with a poor patient prognosis, especially if treatment for SHMs was not administered.

show abstract

Secondary hematological malignancies in patients with sarcoma: A single‑center retrospective study

Jang,

Jeong,

Kong

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Distribution and survival of primary sarcoma in Korea: A single center analysis of 2017 cases

Cited by 1 publication

References 21 publications

Secondary hematological malignancies in patients with sarcoma: A single‑center retrospective study

Secondary hematological malignancies in patients with sarcoma: A single‑center retrospective study

Contact Info

Product

Resources

About